Scilex holding co SCLX.US 總覽分析

美股醫療保健
(SCLX 無簡報檔)

SCLX 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低,若以價值投資為目標且有長期投資部位,需要嚴格執行自己的出場計畫來減持部位

SCLX 近期報酬表現

-8.66%

Scilex holding co

0.38%

同產業平均

-0.07%

S&P500

與 SCLX 同產業的標的表現

  • ZBIO Zenas biopharma inc
    價值 -趨勢 3 分波段 2 分籌碼 2 分股利 1 分
    查看更多

SCLX 公司資訊

Scilex Holding Co. Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

SCLX 股價